Search

Your search keyword '"H. Heslop"' showing total 75 results
Start Over Author "H. Heslop"
75 results on '"H. Heslop"'

1. Hematopoietic Stem/Progenitor Cells and Engineering: Late Breaking Abstract: ALLOGENEIC DONOR-DERIVED CD19-CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR RELAPSED B-CELL MALIGNANCIES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

Author

I.N. Muhsen, H. Cruz, H. Zhang, S.G. Thakkar, B. Grilley, A.P. Gee, H. Heslop, M. Brenner, and C.A. Ramos

Subjects
Cancer Research, Transplantation, Oncology, Immunology, Immunology and Allergy, Cell Biology, Genetics (clinical)
Published
2022
Full Text
View/download PDF

3. CLIN-IMMUNOTHERAPY/BIOLOGIC THERAPIES

Author

I. F. Pollack, R. I. Jakacki, L. Butterfield, H. Okada, Y. Chiba, N. Hashimoto, N. Kagawa, M. Kinoshita, N. Kijima, R. Hirayama, Y. Oji, A. Tsuboi, Y. Oka, H. Sugiyama, T. Yoshimine, R. D. Valle, S. Tejada, S. Inoges, M. A. Idoate, A. L. D. de Cerio, J. Espinos, J. Aristu, J. Gallego, J. P. Calvo, M. Bendandi, J. Zhu, C. Chen, A. Ravelo, E. Yu, R. Dhanda, I. D. Schnadig, L. Zhang, H. Fan, I. Zhang, X. Chen, H. Wang, A. Da Fonseca, B. Badie, L. H. Butterfield, R. L. Hamilton, A. H. Mintz, J. A. Engh, J. Drappatz, M. O. Lively, M. D. Chan, A. M. Salazar, D. M. Potter, E. G. Shaw, F. S. Lieberman, J. Wei, L.-Y. Kong, F. Wang, S. Xu, T. A. Doucette, S. D. Ferguson, Y. Yang, K. McEnery, K. Jethwa, O. Gjyshi, W. Qiao, F. F. Lang, G. Rao, G. N. Fuller, G. A. Calin, A. B. Heimberger, S. Yang, G. E. Archer, H. Miao, X. Cui, W. Xie, D. Snyder, A. J. Pretorian, A. Dechkovskaia, E. Reap, L. A. S. Perez, P. Norberg, R. Schmittling, D. A. Mitchell, J. H. Sampson, F. Lang, G. Calin, D. G. Walker, T. Crough, L. Beagley, C. Smith, L. Jones, R. Khanna, Y. Kanemura, M. Sumida, E. Yoshioka, A. Yamamoto, D. Kanematsu, Y. Matsumoto, H. Fukusumi, A. Takada, M. Nonaka, S. Nakajima, K. Mori, S. Goto, T. Kamigaki, R. Maekawa, T. Shofuda, S. Moriuchi, M. Yamasaki, J. T. Yeung, R. Hamilton, R. Jakacki, I. Pollack, S. Pellegatta, M. Eoli, C. Antozzi, S. Frigerio, M. G. Bruzzone, L. Cuppini, S. Nava, E. Anghileri, G. Cantini, E. Prodi, E. Ciusani, P. Ferroli, M. Saini, G. Broggi, R. Mantegazza, E. A. Parati, G. Finocchiaro, M. Hegde, A. Corder, K. K. Chow, M. Mukherjee, V. S. Brawley, H. E. Heslop, S. Gottschalk, E. Yvon, N. Ahmed, D. M. Gibo, W. Debinski, J. Bonomo, J. Rossmeisl, J. Robertson, P. Dickinson, M. E. Salacz, P. J. Camarata, M. Ots, J. McIntire, D. Lovick, G. Archer, D. Bigner, H. Friedman, D. Lally-Goss, B. Perry, J. Herndon, S. McGehee, R. McLendon, R. E. Coleman, J. Sampson, Z. Grada, T. Byrd, D. R. Shaffer, A. Ghazi, K. Schonfeld, G. Dotti, H. Heslop, W. Wels, M. L. Baker, J. M. Robbins, P. J. Dickinson, D. York, B. K. Sturges, B. Martin, R. J. Higgins, J. Bringas, K. Bankiewicz, H. E. Gruber, D. J. Jolly, A. Narayana, M. Mathew, R. Kannan, K. Madden, J. Golfinos, E. Parker, P. Ott, A. Pavlick, D. A. Bota, C. Pretto, P. Hantos, F. M. Hofman, T. C. Chen, J. A. Carrillo, V. E. Schijns, A. A. Stathopoulos, R. M. Prins, R. Everson, H. Soto, D. N. Lisiero, E. Young, L. M. Liau, A. Friedman, D. D. Bigner, D. Boczkowski, S. G. Gururangan, G. Grant, T. Driscoll, J. King, S. Nair, H. Fuchs, J. Kurtzberg, M. A. Shevtsov, A. V. Pozdnyakov, A. V. Kim, K. A. Samochernych, I. V. Guzhova, I. V. Romanova, B. A. Margulis, and W. A. Khachatryan

Subjects
Abstracts, Cancer Research, Oncology, business.industry, medicine.medical_treatment, Biologic therapies, Medicine, Neurology (clinical), Immunotherapy, Bioinformatics, business
Published
2012
Full Text
View/download PDF

4. HIGH GRADE GLIOMAS

Author

A. Leonard, J. Wolff, R. Sengupta, J. Marassa, D. Piwnica-Worms, J. Rubin, I. Pollack, R. Jakacki, L. Butterfield, H. Okada, J. Fangusaro, K. E. Warren, C. Mullins, P. Jurgen, S. Julia, C. C. Friedrich, S. Keir, J. Saling, M. Roskoski, H. Friedman, D. Bigner, C. Moertel, M. Olin, T. Dahlheimer, M. Gustafson, D. Sumstad, D. McKenna, W. Low, D. Nascene, A. Dietz, J. Ohlfest, D. Sturm, H. Witt, V. Hovestadt, D. A. K. Quan, D. T. W. Jones, C. Konermann, E. Pfaff, A. Korshunov, M. Rizhova, T. Milde, O. Witt, M. Zapatka, V. P. Collins, M. Kool, G. Reifenberger, P. Lichter, A. M. Lindroth, C. Plass, N. Jabado, S. M. Pfister, B. Pizer, A. Salehzadeh, A. Brodbelt, C. Mallucci, M. Brassesco, J. Pezuk, A. Morales, J. de Oliveira, G. Roberto, K. Umezawa, E. Valera, E. Rego, C. Scrideli, L. Tone, S. J. E. Veringa, D. G. Van Vuurden, P. Wesseling, W. P. Vandertop, D. P. Noske, T. Wurdinger, G. J. L. Kaspers, E. Hulleman, K. Wright, A. Broniscer, A. Bendel, D. Bowers, J. Crawford, P. Fisher, T. Hassall, G. Armstrong, J. Baker, I. Qaddoumi, G. Robinson, C. Wetmore, P. Klimo, F. Boop, A. Onar-Thomas, D. Ellison, A. Gajjar, O. Cruz, C. de Torres, M. Sunol, E. Rodriguez, L. Alonso, A. Parareda, T. Cardesa, H. Salvador, V. Celis, A. Guillen, G. Garcia, J. Muchart, C. Trampal, M. L. Martin, M. Rebollo, J. Mora, A. Piotrowski, A. Kowalska, P. Coyle, S. Smith, H. Rogers, D. Macarthur, R. Grundy, D. Puccetti, S. Salamat, T. Kennedy, N. Patel, K. Bradley, K. Casey, B. Iskandar, Y. Nakano, K. Okada, Y. Osugi, K. Yamasaki, H. Fujisaki, H. Fukushima, T. Inoue, Y. Matsusaka, H. Sakamoto, J. Hara, S. De Vleeschouwer, H. Ardon, F. Van Calenbergh, R. Sciot, G. Wilms, J. Van Loon, J. Goffin, S. Van Gool, D. Rusinak, P. Knight, K. Onel, D. Wargowski, A. Stettner, A. Al-Ghafari, W. Punjaruk, B. Coyle, I. Kerr, E. Xipell, M. Rodriguez, M. Gonzalez-Huarriz, M. T. Tunon, I. Zazpe, S. Tejada-Solis, R. Diez-Valle, J. Fueyo, C. Gomez-Manzano, M. M. Alonso, D. Pastakia, C. McCully, R. Murphy, J. Bacher, M. Thomas, E. Steffen-Smith, K. Saleem, S. Waldbridge, B. Widemann, K. Warren, E. Miele, F. Buttarelli, A. Arcella, F. Begalli, A. Po, C. Baldi, G. Carissimo, M. Antonelli, V. Donofrio, I. Morra, P. Nozza, A. Gulino, F. Giangaspero, E. Ferretti, I. Elens, F. Pauwels, S. Fritzell, S. Eberstal, E. Sanden, E. Visse, A. Darabi, P. Siesjo, P. McDonald, J. Wrogemann, S. Krawitz, M. Del Bigio, D. Eisenstat, R. Kwiecien, T. Pietsch, A. Faldum, R.-D. Kortmann, M. Warmuth-Metz, S. Rutkowski, I. Slavc, C. M. Kramm, U. Uparkar, R. Geyer, R. Ermoian, R. Ellenbogen, S. Leary, J. Triscott, K. Hu, A. Fotovati, S. Yip, R. Kast, B. Toyota, S. Dunn, M. Hegde, A. Corder, K. Chow, M. Mukherjee, A. Ashoori, V. Brawley, H. Heslop, S. Gottschalk, E. Yvon, N. Ahmed, T.-T. Wong, F.-Y. Yang, M. Lu, H.-F. Liang, H.-E. Wang, R.-S. Liu, M.-C. Teng, C.-C. Yen, S. Agnihotri, C. Ternamian, C. Jones, G. Zadeh, J. Rutka, C. Hawkins, I. Filipek, M. Drogosiewicz, M. Perek-Polnik, E. Swieszkowska, B. D. Baginska, E. Jurkiewicz, D. Perek, A. Kuehn, F. Falkenstein, A. Gnekow, C. Kramm, M. D. Brooks, E. Jackson, R. D. Mitra, J. B. Rubin, X.-Y. Liu, J. Schwartzentruber, A. M. Fontebasso, D.-A. K. Quang, S. Albrecht, Z. Dong, P. Siegel, A. Von Diemling, D. Faury, U. Tabori, J. Majewski, R. Lulla, M. Echevarria, T. Alden, A. DiPatri, T. Tomita, S. Goldman, T. Lin, T. E. Merchant, M. Kocak, A. P. Panandiker, G. T. Armstrong, G. H. Gielen, A. z. Muehlen, C. Hubert, Y. Ding, C. Toledo, P. Paddison, J. Olson, M. Nandhabalan, L. Bjerke, D. Bax, D. Carvalho, I. Bajrami, A. Ashworth, C. Lord, D. Hargrave, R. Reis, P. Workman, S. Little, S. Popov, A. Jury, A. Burford, L. Doey, S. Al-Sarraj, J. Jurgensmeier, L. Chen, I. Kozarewa, S. Baker, L. Perryman, G. Box, F. Raynaud, S. Eccles, M. Viana-Pereira, M. Pereira, T. Forshew, R. Tatevossian, D. Sheer, J. Pimental, M. Pires, C. Sarkar, P. Jha, I. R. P. Patrick, K. Somasundaram, P. Pathak, M. C. Sharma, V. Suri, A. Suri, N. Gerges, T. Haque, A. Nantel, C. Lee, J. Chen, C. Venugopal, A. Singhal, C. Dunham, J. Kerr, M. Verreault, H. Wakimoto, A. Jayanthan, A. Narendran, S. Singh, G. Giraud, S. Holm, B. Gustavsson, R. Kizyma, Z. Kizyma, L. Dvornyak, B. Kotsay, S. Epari, P. Sharma, M. Gurav, T. Gupta, P. Shetty, A. Moiyadi, S. Kane, and R. Jalali

Subjects
Abstracts, 03 medical and health sciences, Cancer Research, 0302 clinical medicine, Oncology, business.industry, 030220 oncology & carcinogenesis, Medicine, Neurology (clinical), business, 030217 neurology & neurosurgery
Published
2012
Full Text
View/download PDF

5. Immunotherapy

Author

M. Fujita, G. Kohanbash, H. A. McDonald, L. Delamarre, S. A. Decker, J. R. Ohlfest, H. Okada, P. Kalinski, R. Ueda, A. Hoji, T. E. Donegan, A. H. Mintz, J. A. Engh, D. L. Bartlett, C. K. Brown, H. Zeh, M. P. Holtzman, T. A. Reinhart, T. L. Whiteside, L. H. Butterfield, R. L. Hamilton, D. M. Potter, I. F. Pollack, A. M. Salazar, F. S. Lieberman, M. R. Olin, B. M. Andersen, P. T. Grogan, M. Hunt, F. E. Popescu, Z. L. Xiong, C. Seiler, C. L. Forster, K. S. SantaCruz, W. Chen, B. R. Blazar, J. Hu, C. J. Wheeler, S. Phuphanich, J. Rudnick, M. Nuno, N. Serrano, J. Dantis, J. Richardson, M. Mazer, H. Q. Wang, R. Chu, K. L. Black, J. Yu, Y. M. Li, D. A. Vallera, W. A. Hall, J. D. Rudnick, R. M. Chu, H. Wang, J. S. Yu, I. Yang, S. Han, T. Tihan, M. Wrensch, A. T. Parsa, M. A. Hunt, J. L. Gallardo, G. E. Pluhar, C. E. Brown, R. Starr, C. Martinez, J. Bading, J. A. Ressler, B. Badie, M. C. Jensen, R. P. Glick, A. Ksendzovsky, R. Zengou, P. Polak, V. Simonini, T. Lichtor, D. Feinstein, K. K. Chow, N. Ahmed, V. S. Salsman, Y. Kew, S. Powell, R. Grossman, H. E. Heslop, S. Gottschalk, F. H. Barnett, V. Marchetti, M. Wang, A. Johnson, L. Scheppke, R. Jacobson, G. Nemerow, M. Friedlander, V. Salsman, A. M. Leen, C. M. Bollard, C. Rooney, P. Z. New, B. Salvoldo, and H. Heslop

Subjects
Cancer Research, Oncology, Neurology (clinical)
Published
2010
Full Text
View/download PDF

6. Tumor immunity and immunosurveillance (PP-093)

Author

G. Bi, K. Hanada, M. Maeda, W. J. Norde, A. Piwko-Czuchra, M. Hojjat-Farsangi, C. Tsai, G. Ball, C. Sarkar, Alireza Razavi, U. Yamashita, A. Jamali, O. Gavriliuc, S. Darzi, W. Wang, V. Subr, Y. Endo, M. Mehrabi Bahar, M. Hung, M. W. L. Teng, M. Miiluniemi, R. Sen, S. Bae, H. C. Hung, A. Anjomshoaa, L. Cazin, D. Zhao, I. J. Shubina, R. Maekawa, M. Shin-ya, M. Pfreundschuh, S. M. ElZoghaby, T. A. Luger, A. Nabi, N. Minato, Y. Kao, M. S. Alam, R. Spisek, M. Maki, V. Huovinen, T. Murata, R. Anderson, E. Nicholson, M. van Egmond, J. Tomala, C. Wang, W. Sun, M. Momeny, S. Lee, M. L. Mora-García, N. Alizadeh, D. Jin, I. Comerford, E. P. Kisseleva, R. M. Talaat, S. Kim, D. Wakita, J. Strid, M. Shimomura, S. Wang, Y. Tamura, Y. Tanaka, J. Ichikawa, M. Inaba, H. Lee, R. Nohra, P. Hu, J. Sun, N. Okazaki, K. Franciszkiewicz, G. M. Fadaly, M. Maksimow, A. Rosca, W. L. Olszewski, T. Inozume, Y. Zhang, S. F. Ngiow, H. K. Takahashi, M. H. Huang, S. Hashino, H. Li, K. S. Titov, H. C. Toh, H. Lim, T. Yaguchi, M. Bögels, B. Kubuschok, M. Wang, G. Nunez, A. Pourazar, F. Mami-Chouaib, P. Rossmann, K. Moriya, A. Eric, N. Li, S. Ichimiya, R. Kumar, H. Mao, L. H. El Sayed, T. Chen, I. Kuiatse, Y. M. Tzeng, A. V. Schattenberg, G. Kristiansen, Y. Mizote, P. Lei, Y. Harata-Lee, H. Ihn, M. R. Khorramizadeh, M. R. Egeler, B. Sumer, H. Kim, S. Gnjatic, C. K. Lee, R. Kiessling, Y. Tomita, Y. Ji, E. A. Starickova, J. Kopecny, E. Nakazawa, M. W. Teng, D. J. DiLillo, M. E. Castro-Manrreza, S. N. M. AbouRawach, J. C. Wallace, Mahmood Jeddi-Tehrani, H. I. Huang, T. Sakurai, F. Golsaz Shirazi, M. Schaap, Y. Nishimura, N. M. AbouRawach, W. Yang, A. Zamani, S. Hong, A. Wakabayashi, K. Berg Lorvik, W. Shi, E. Nakayama, V. Raina, D. Jung, D. J. Cole, A. Hosoi, B. Becher, L. Keyue, T. Torigoe, J. Hasheminia, H. Matsuda, Y. Adachi, V. Bronte, E. Kato, M. H. Andersen, B. Weiss-Steider, K. Sumida, A. Gruia, M. Voskort, M. Mandai, H. Baba, A. Korman, Z. Qin, M. Khorramizadeh, B. Rihova, G. E. Lyons, H. Yoon, T. Tang, C. A. Hansen, M. Nakatsugawa, Y. Kim, C. Soderberg Naucler, M. Harada, P. Kralikova, M. Hajzadeh, M. Hoseinipanah, A. Uenaka, S. Inoda, C. Gest, N. Shibagaki, M. Quigley, O. S. Naga, J. Chen, H. Liu, T. Ito, M. Saberi-Firoozi, J. Khoshnoodi, F. Zhu, H. M. Ghoneim, R. Esmaeili, Z. Jahanshiri, J. Lee, Y. Hirohashi, N. Hosaka, A. Berahmeh, M. Bodogai, I. Markovic, N. Fu, M. Hong, Y. Kanthaiah, J. D. Holland, J. King, H. S. Kang, X. Huang, M. Brenner, S. Anghel, S. Nagoya, J. Soria, I. Konishi, M. Kato, J. Shin, N. Sato, R. Beelen, G. K. Brown, Y. J. Zhuang, K. Ulbrich, S. Senju, T. Kishida, J. Fucikova, J. Kim, Iwona Hus, F. Xu, M. Inoue, M. Shabani, Lorenzo Mortara, L. Zheng, S. Ghaffari, N. Ozoren, K. Nakatsuka, E. Gélizé, M. Zhang, R. Korenstein, W. Li, P. Marrack, A. Feng, B. Toh, N. Matsumura, R. A. Kemp, J. Hernández-Montes, S. Werner, C. M. Diaz-Montero, H. Hayashi, X. Zha, T. F. Tedder, Y. Wu, E. Torkabadi, A. Choudhury, M. Asaka, Y. Bi, C. C. Johansson, K. Kakimi, Y. G. Mansurova, K. Oida, Y. Kusumoto, M. J. Smyth, C. J. Chen, H. L. Dong, Jamshid Hadjati, I. Besu-Zizak, T. Takeuchi, O. Buyanovskaya, A. V. Krylov, I. Juko-Pecirep, M. A. Firer, A. Girardin, M. Fukuda, K. T. Y. H. Hiroshi Shiku, I. Mahmud, S. Jalkanen, S. H. Tu, N. K. Akhmatova, M. Hajimoradi, K. Udaka, X. Zhang, S. Beissert, Y. Urade, K. Ghaffarzadehgan, J. Strohalm, Z. Han, C. Akekawatchai, X. Cao, M. V. Kiselevsky, Y. Keisari, T. Tan, T. Yoshikawa, S. Muto, D. Mougiakakos, H. Dolabi, Q. Wang, H. Nakano, S. R. Hadrup, V. Frangione, Roberto S. Accolla, Y. Hwang, H. Mochimaru, R. Okita, K. Ohmori, H. Sima, J. Prieto, S. A. Rosenberg, I. Poschke, M. I. Nishimura, J. Medina, P. Wen, Y. Lu, R. Hadavi, A. Corthay, Y. Kawakami, S. Bao-en, M. Yousefi, M. S. Hassan, M. Torabi Rahvar, S. Mohanty, P. Nagarkatti, E. A. Lebedinskaya, Y. Li, V. Paunescu, Y. Zheng, E. Hafez, Y. H. Lee, W. Song, K. Soliman, W. Gao, M. Matsui, Z. Juranic, K. Hebeda, R. Gress, T. Kishimoto, C. Zhang, Q. Xie, C. A. Rosenstadt, K. Klimesova, J. Zhou, S. Kawaguchi, B. Clausen, J. Jiang, Magdalena Wasiak, N. Sakemura, J. L. Teillaud, H. M. Koheil, M. Ahmad, N. Ding, M. Jevric, I. V. Lyamina, Z. Zakostelska, M. Soengas, T. Takaki, H. Dai, D. Mehrabani, K. Aritake, D. Chen, J. Kato, M. Djordjevic, S. Fukushima, I. M. Svane, A. Rahbar, T. Nishimura, B. Kharma, M. W. Schilham, I. Entin, B. von Scheidt, T. Taguchi, Y. Nakashima, D. Preuss, K. Mimura, A. Tominaga, T. Fujita, K. Kido, H. Raziee, S. Ikehara, T. Komatsu, H. Yagura, Y. Yoshida, G. Capone, X. Wang, R. Varin, N. Kumagai, M. Kochetkova, A. Hayday, M. Karikoski, Chun-Yen Chang, H. Maeng, S. Sugawara, S. Ghadri, H. Chmelova, A. Sun, W. Pei'e, L. A. Sherman, A. Puaux, A. Amari, E. Saller, W. H. Fridman, N. Junker, M. Sarafraz yazdi, K. Wejksza, M. Kovar, H. Yang, C. Hu, Y. Arima, A. Le Floc'h, Y. Nakamura, R. Morita, Y. Iwakura, H. Oster, M. Zabala, I. Z. Matic, V. Chew, A. Memarian, G. Jiang, B. Huang, I. Hammami, T. N. M. Schumacher, P. Vossough, N. Tsukamoto, V. I. Lioudyno, M. Sirova, M. Oka, J. Eyles, H. Madadi, H. Stauss, A. Itai, L. U'Ren, B. Tsai, H. W. Chen, X. Qu, R. García-Rocha, Y. Goto, H. Ozaki, Patrizia Castellani, Q. Shao, K. Wang, A. Talei, E. Ivansson, C. L. Wang, J. J. Montesinos-Montesinos, H. Dolstra, D. Nistor, M. Li, S. Hirata, T. Etrych, X. M. Gao, L. Li, O. Mazda, D. Andrews, B. Ansaripour, P. Yotnda, Q. J. Wang, T. Tsukahara, J. Bartunkova, H. Lei, H. Fredrix, A. De Lerma Barbaro, G. R. Fajardo-Orduña, Paulina Wdowiak, L. Gunn, W. Zuo, Q. Zhang, T. Sparwasser, S. Chen, Y. Yang, L. Liu, Y. Kikuchi, T. Aji, S. Nakai, K. H. Lim, M. M. Andalib, H. Norell, U. V. Ozkurede, T. Shimada, A. Andalib, J. Slansky, Xiao-Tong Yuan, P. Chong, Y. Miura, J. Inoue, T. Yamashita, Y. Faghani, S. Hosseini, H. Hosseinnezhad, K. Dan, Q. Liu, C. Park, A. Prevost-Blondel, A. Tomar, H. Pfister, S. Okano, H. Harimoto, H. J. Baelde, S. Shimada, J. Vom Berg, B. Deng, J. C. Becker, S. Samarghandian, A. K. Chávez-Rueda, J. C. Yang, A H Zarnani, T. Nakatsura, N. Erfani, R. van der Voort, R. C. Rees, X. Wen, V. Gutierrez-Serrano, H. Kishimoto, A. Ghaderi, H. Ren, Y. Zhong, A. Lankester, A. Amini, S. A. Williams, G. Jin, M. Mittelman, P. Thor Straten, I. Ng, T. Suzuki, C. Tovar, N. Harashima, Y. Oshima, I. V. Oradovskaya, M. Mahmoudian, I. C. Le Poole, Y. Furukawa, V. Budinsky, Y. Liu, M. Hori, Nazanin Mojtabavi, H. Rabbani, S. A. Shamsdin, Z. Tayarani, H. Fan, Y. Hayashida, K. Iwamura, B. Bogen, S. Vivekanandhan, V. Phillips, L. Berge-Hansen, Q. Yin, N. Lee, Y. Sasaki, Q. Li, M. Nishibori, K. Sato, N. D. Spivey, G. Y. Liu, H. Asanuma, H. Kang, R. Ophir, H. Mellstedt, D. Crisnic, A. Irie, J. Klarquist, B. Seliger, H. Wake, N. McLaughlin, S. Park, D. Vetvicka, J. T. Baran, I. Gustavsson, N. Arandi, Y. Sher, J. Kong, T. Ando, L. Volkova, J. Yan, H. Fang, N. Matumura, M. Arjipour, D. Handke, M. Ghasemi, A. E. Reeve, P. Berraondo, O. Hovorka, P. Chow, R. A. Sharifian, G. Shen, G. Hu, S. J. Liu, R. Abès, H. Takahashi, Anna Dmoszynska, C. A. Don-López, N. Tajik, H. Hwang, N. Gül, K. Horie, N. Rahbar-Roshandel, F. M. Bojin, D. Li, J. Hamanishi, H. Heslop, Jacek Roliński, M. Shimizu, J. Wang, T. Hirano, H. Sumimoto, R. B. Sørensen, G. M. Woods, N. Borojevic, S. Stevanovic, M. K. Zaman, Z. Fu, E. Morris, A. Al-Khami, M. Kverka, W. Shi-jie, A. Yano, M. Gewartowska, H. Okuyama, S. Kale, J. P. Vannier, F. Ciuculescu, K. Loser, Z. Zhang, U. Joimel, F. M. Maas, C. Lemetre, A. H. M. Taminiau, J. Tavakkol Afshari, M. Sang, M. Cristea, D. Tobi, M. Motamedi, X. Zhao, Y. Hisa, J. P. Abastado, S. I. Lin, L. Cao, Y. Yoshioka, M. Isobe, M. Murakami, H. Hisha, V. Younesi, N. Krug, M. Ahmadzadeh, E. Saka, Z. Zhan, C. Bunu, A. Monroy-García, S. Wu, Y. Ohue, B. Matharoo-Ball, A. Emami, R. Bos, F. Shokri, W. Xing, T. Suda, O. V. Lebedinskaya, J. Ishizaki, T. Ramadan, G. Brown, S. Mori, A. Rezaei, H. Haro, R. Xia, T. Tsunoda, Y. Narita, Y. Jin, A. Biragyn, H. Irjala, P. C. W. Hogendoorn, J. Betka, C. Kudo-Saito, S. Xiaobai, Y. Sung, M. Moscicka-Wesolowska, T. Baba, A. Saad, W. Lee, A. A. Pourfathollah, G. R. Hill, A. Davari sadat, M. Hattori, J. Nisanov, S. Santos, L. Chen, P. Vosough, J. Zhang, T. Martins da Palma, T. M. de Witte, Z. M. Hassan, A. Kreiss, Y. Saitou, L. Zhang, S. R. McColl, T. Hudcovic, J. Yeh, M. Oft, L. Jianing, L. Han, K. Kitaoka, O. Moaven, X. Liu, X. Ren, C. A. Taher, H. Kitamura, A. Tanaka, Y. Ikuta, N. Ardaiz, S. Arab, J. Fioravanti, Agnieszka Bojarska-Junak, S. Rezaie, H. Tlaskalova Hogenova, A. Takahashi, C. Soria, W. Zibing, T. Wan, J. Kang, U. Gyllensten, A. Swanson, L. Ong, X. Jiang, M. M. Amiri, M. Ahmadi, S. Fan, C. A. Tatu, D. Berghuis, T. Abdolahi, J. Guosheng, A. Nardin, H. Asgarian-Omran, B. Vafadar-Isfahani, M. Salmi, S. Smola, R. Saeedi, R. Imamura, M. Jolicoeur, S. Liu, L. Yang, P. Wang, L. L. Pritchard, Z. Li, B. Damdinsuren, X. Lu, M. Lee, T. Nakagawa, J. Liu, B. Chiang, G. Tanasie, M. Kano, S. Ngiow, M. Nooridaloii, M. Antsiferova, K. Harada, S. Eikawa, M. Eisenring, F. Neumann, J. R. Wunderlich, K. Yoshimoto, K. Abiko, T. Otsuki, M. Jafarzadeh, Y. F. Liao, E. Blot, Y. Nagai, G. De Crescenzo, M. Yekaninejad, Y. Noguchi, M. Nagarkatti, P. B. Olkhanud, M. Inic, C. Prakash, C. Tatu, S. Ono, A. Lindbloom, F. Marttila-Ichihara, R. Abe, T. Okamoto, and K. Yanaba

Subjects
Immunosurveillance, business.industry, Immunology, Cancer research, Immunology and Allergy, Medicine, General Medicine, Tumor immunity, business
Published
2010
Full Text
View/download PDF

10. HIGH GRADE GLIOMAS AND DIPG

Author

C. F. Classen, D. William, M. Linnebacher, A. Farhod, W. Kedr, B. Elsabe, S. Fadel, S. Van Gool, S. De Vleeschouwer, C. Koks, A. Garg, M. Ehrhardt, M. Riva, P. Agostinis, N. Graf, T.-W. Yao, Y. Yoshida, J. Zhang, T. Ozawa, D. James, T. Nicolaides, R. Kebudi, F. B. Cakir, O. Gorgun, F. Y. Agaoglu, E. Darendeliler, A. Al-Kofide, E. Al-Shail, Y. Khafaga, H. Al-Hindi, M. Dababo, A. U. Haq, M. Anas, M. G. Barria, K. Siddiqui, M. Hassounah, M. Ayas, S. V. van Zanten, M. Jansen, D. van Vuurden, M. Huisman, D. Vugts, O. Hoekstra, G. van Dongen, G. Kaspers, J. Cockle, E. Ilett, K. Scott, A. Bruning-Richardson, S. Picton, S. Short, A. Melcher, M. Benesch, M. Warmuth-Metz, A. O. von Bueren, M. Hoffmann, T. Pietsch, R.-D. Kortmann, M. Eyrich, S. Rutkowski, M. C. Fruhwald, J. Faber, C. Kramm, M. Porkholm, L. Valanne, T. Lonnqvist, S. Holm, B. Lannering, P. Riikonen, D. Wojcik, A. Sehested, N. Clausen, A. Harila-Saari, E. Schomerus, H. K. Thorarinsdottir, P. Lahteenmaki, M. Arola, H. Thomassen, U. M. Saarinen-Pihkala, S.-M. Kivivuori, P. Buczkowicz, C. Hoeman, P. Rakopoulos, S. Pajovic, A. Morrison, E. Bouffet, U. Bartels, O. Becher, C. Hawkins, T. W. A. Gould, C. V. Rahman, S. J. Smith, D. A. Barrett, K. M. Shakesheff, R. G. Grundy, R. Rahman, N. Barua, D. Cronin, S. Gill, S. Lowisl, A. Hochart, C.-A. Maurage, N. Rocourt, M. Vinchon, O. Kerdraon, F. Escande, J. Grill, V. K. Pick, P. Leblond, G. Burzynski, T. Janicki, S. Burzynski, A. Marszalek, N. Ramani, W. Zaky, G. Kannan, A. Morani, D. Sandberg, L. Ketonen, O. Maher, F. Corrales-Medina, H. Meador, S. Khatua, M. Brassesco, L. Delsin, G. Roberto, C. Silva, L. Ana, E. Rego, C. Scrideli, K. Umezawa, L. Tone, S. J. Kim, C.-Y. Kim, I.-A. Kim, J. H. Han, B.-S. Choi, H. S. Ahn, H. S. Choi, F. Haque, R. Layfield, R. Grundy, L. Gandola, E. Pecori, V. Biassoni, E. Schiavello, C. Chiruzzi, F. Spreafico, P. Modena, F. Bach, E. Pignoli, M. Massimino, M. Drogosiewicz, B. Dembowska-Baginska, E. Jurkiewicz, I. Filipek, M. Perek-Polnik, E. Swieszkowska, D. Perek, S. Bender, D. T. Jones, H.-J. Warnatz, B. Hutter, T. Zichner, J. Gronych, A. Korshunov, R. Eils, J. O. Korbel, M.-L. Yaspo, P. Lichter, S. M. Pfister, S. Yadavilli, O. J. Becher, M. Kambhampati, R. J. Packer, J. Nazarian, F. C. Lechon, L. Fowkes, K. Khabra, L. M. Martin-Retortillo, L. V. Marshall, S. Vaidya, D.-M. Koh, M. O. Leach, A. D. Pearson, S. Zacharoulis, D. Schrey, G. Barone, E. Panditharatna, M. Stampar, A. Siu, H. Gordish-Dressman, J. Devaney, E. I. Hwang, A. H. Chung, R. K. Mittapalli, W. F. Elmquist, D. Castel, M.-A. Debily, C. Philippe, N. Truffaux, K. Taylor, R. Calmon, N. Boddaert, L. Le Dret, P. Saulnier, L. Lacroix, A. Mackay, C. Jones, S. Puget, C. Sainte-Rose, T. Blauwblomme, P. Varlet, N. Entz-Werle, C. Maugard, G. Bougeard, A. Nguyen, M. P. Chenard, A. Schneider, M. P. Gaub, M. Tsoli, A. Vanniasinghe, P. Luk, P. Dilda, M. Haber, P. Hogg, D. Ziegler, S. Simon, M. Monje, K. Gurova, A. Gudkov, M. Zapotocky, M. Churackova, B. Malinova, J. Zamecnik, M. Kyncl, M. Tichy, A. Puchmajerova, J. Stary, D. Sumerauer, J. Boult, M. Vinci, L. Perryman, G. Box, A. Jury, S. Popov, W. Ingram, S. Eccles, S. Robinson, S. Emir, H. A. Demir, C. Bayram, F. Cetindag, G. B. Kabacam, A. Fettah, J. Li, Y. Jamin, C. Cummings, J. Bamber, R. Sinkus, M. Nandhabalan, L. Bjerke, A. Burford, A. von Bueren, M. Baudis, P. Clarke, I. Collins, P. Workman, N. Olaciregui, J. Mora, A. Carcaboso, A. Bullock, M. Alonso, C. de Torres, O. Cruz, E. Pencreach, F. M. Moussalieh, D. Guenot, I. Namer, I. Pollack, R. Jakacki, L. Butterfield, R. Hamilton, A. Panigrahy, D. Potter, A. Connelly, S. Dibridge, T. Whiteside, H. Okada, S. Ahsan, E. Raabe, M. Haffner, K. Warren, M. Quezado, L. Ballester, C. Eberhart, F. Rodriguez, C. Ramachandran, S. Nair, K.-W. Quirrin, Z. Khatib, E. Escalon, S. Melnick, M. Hofmann, I. Schmid, T. Simon, E. Maass, A. Russo, G. Fleischhack, M. Becker, H. Hauch, A. Sander, C. Grasso, N. Berlow, L. Liu, L. Davis, E. Huang, P. Woo, Y. Tang, A. Ponnuswami, S. Chen, Y. Huang, M. Hutt-Cabezas, L. Dret, P. Meltzer, H. Mao, J. Abraham, M. Fouladi, M. N. Svalina, N. Wang, E. Hulleman, X.-N. Li, C. Keller, P. T. Spellman, R. Pal, M. H. A. Jansen, A. C. P. Sewing, T. Lagerweij, D. J. Vuchts, D. G. van Vuurden, V. Caretti, P. Wesseling, G. J. L. Kaspers, K. Cohen, M. Pearl, M. Kogiso, L. Zhang, L. Qi, H. Lindsay, F. Lin, S. Berg, J. Muscal, N. Amayiri, U. Tabori, B. Campbel, D. Bakry, M. Aronson, C. Durno, S. Gallinger, D. Malkin, I. Qaddumi, A. Musharbash, M. Swaidan, M. Al-Hussaini, S. Shandilya, C. McCully, R. Murphy, S. Akshintala, D. Cole, R. P. Macallister, R. Cruz, B. Widemann, R. Salloum, A. Smith, M. Glaunert, A. Ramkissoon, S. Peterson, S. Baker, L. Chow, J. Sandgren, S. Pfeifer, S. Popova, I. Alafuzoff, T. D. de Stahl, S. Pietschmann, M. J. Kerber, I. Zwiener, G. Henke, K. Muller, N. Y.-F. Sieow, R. H. M. Hoe, A. M. Tan, M. Y. Chan, S. Y. Soh, K. Burrell, Y. Chornenkyy, M. Remke, B. Golbourn, M. Barzczyk, M. Taylor, J. Rutka, P. Dirks, G. Zadeh, S. Agnihotri, R. Hashizume, Y. Ihara, N. Andor, X. Chen, R. Lerner, X. Huang, M. Tom, D. Solomon, S. Mueller, C. Petritsch, Z. Zhang, N. Gupta, T. Waldman, A. Dujua, J. Co, F. Hernandez, D. Doromal, M. Hegde, A. Wakefield, V. Brawley, Z. Grada, T. Byrd, K. Chow, S. Krebs, H. Heslop, S. Gottschalk, E. Yvon, N. Ahmed, G. Cornilleau, J. Paulsson, F. Andreiuolo, L. Guerrini-Rousseau, B. Geoerger, G. Vassal, A. Ostman, D. W. Parsons, L. R. Trevino, F. Gao, X. Shen, O. Hampton, M. Kosigo, P. A. Baxter, J. M. Su, M. Chintagumpala, R. Dauser, A. Adesina, S. E. Plon, D. A. Wheeler, C. C. Lau, G. Gielen, A. z. Muehlen, R. Kwiecien, J. Wolff, R. R. Lulla, J. Laskowski, S. Goldman, V. Gopalakrishnan, J. Fangusaro, M. Kieran, A. Fontebasso, S. Papillon-Cavanagh, J. Schwartzentruber, H. Nikbakht, N. Gerges, P.-O. Fiset, D. Bechet, D. Faury, N. De Jay, L. Ramkissoon, A. Corcoran, D. Jones, D. Sturm, P. Johann, T. Tomita, M. Nagib, A. Bendel, L. Goumnerova, D. C. Bowers, J. R. Leonard, J. B. Rubin, T. Alden, A. DiPatri, S. Browd, S. Leary, G. Jallo, M. D. Prados, A. Banerjee, A.-S. Carret, B. Ellezam, L. Crevier, A. Klekner, L. Bognar, P. Hauser, M. Garami, J. Myseros, Z. Dong, P. M. Siegel, W. Gump, K. Ayyanar, J. Ragheb, M. Krieger, E. Kiehna, N. Robison, D. Harter, S. Gardner, M. Handler, N. Foreman, B. Brahma, T. MacDonald, H. Malkin, S. Chi, P. Manley, P. Bandopadhayay, L. Greenspan, A. Ligon, S. Albrecht, K. L. Ligon, J. Majewski, N. Jabado, F. Cordero, K. Halvorson, I. Taylor, M. Hutt, M. Weingart, A. Price, M. Kantar, S. Onen, S. Kamer, T. Turhan, O. Kitis, Y. Ertan, N. Cetingul, Y. Anacak, T. Akalin, Y. Ersahin, G. Mason, C. Ho, F. Crozier, G. Vezina, R. Packer, E. Hwang, S. Gilheeney, N. Millard, K. DeBraganca, Y. Khakoo, K. Kramer, S. Wolden, M. Donzelli, C. Fischer, M. Petriccione, I. Dunkel, S. Afzal, A. Fleming, V. Larouche, S. Zelcer, D. L. Johnston, M. Kostova, C. Mpofu, J.-C. Decarie, D. Strother, L. Lafay-Cousin, D. Eisenstat, C. Fryer, J. Hukin, M. Hsu, J. Lasky, T. Moore, L. Liau, T. Davidson, R. Prins, T. Hassal, J. Baugh, J. Kirkendall, R. Doughman, J. Leach, B. Jones, L. Miles, D. Hargrave, T. Jacques, S. Savage, D. Saunders, R. Wallace, B. Flutter, D. Morgenestern, E. Blanco, K. Howe, M. Lowdell, E. Samuel, A. Michalski, J. Anderson, Y. Arakawa, K. Umeda, K.-i. Watanabe, T. Mizowaki, M. Hiraoka, H. Hiramatsu, S. Adachi, T. Kunieda, Y. Takagi, S. Miyamoto, S. Venneti, M. Santi, M. M. Felicella, L. M. Sullivan, I. Dolgalev, D. Martinez, A. Perry, P. W. Lewis, D. C. Allis, C. B. Thompson, and A. R. Judkins

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, 03 medical and health sciences, Abstracts, 0302 clinical medicine, Text mining, 030220 oncology & carcinogenesis, Internal medicine, medicine, Neurology (clinical), business, 030217 neurology & neurosurgery
Published
2014

11. [Contribution of antineoplastic biotherapy in the treatment of leukemia in children]

Author

R, Rousseau, C, Bollard, and H, Heslop

Subjects
Biological Therapy, Leukemia, Retroviridae, Lentivirus, Humans, Genetic Therapy, Immunotherapy, Child, Adenoviridae
Abstract

Improvements in the chemotherapeutic and transplant regimens have had a significant impact in improving survival rates for pediatric leukemia. However, there are still major problems to address including what options are available for patients with chemoresistant disease and what strategies are available to avoid toxicity associated with highly cytotoxic treatment regimens. Gene and immunotherapy protocols hold great promise. Using gene transfer of a marker gene, a number of biologic issues in the therapy of leukemia have been addressed. For example, by gene marking autologous bone marrow grafts it has been possible to demonstrate that infused marrow contributes to relapse in acute and chronic myeloid leukemias. In the allogeneic transplant setting, genetically modified T-cells have proven valuable for the prophylaxis and treatment of viral diseases and may have an important role in preventing or treating disease relapse. Gene transfer is also being used to modify tumor function, enhance immunogenicity, and confer drug-resistance to normal hematopoietic stem cells. With the continued scientific advancements in this field, gene therapy will almost certainly have a major impact on the treatment of pediatric leukemia in the future.

Published
2002

12. Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease

Author

R K, Burt, M, Brenner, W, Burns, E, Courier, G, Firestein, B, Hahn, H, Heslop, C, Link, H, McFarland, M, Roland, M, Territo, G, Tsokos, and A, Traynor

Subjects
Clinical Trials, Phase II as Topic, Clinical Trials, Phase I as Topic, Genetic Vectors, Hematopoietic Stem Cell Transplantation, Humans, Hematopoietic Stem Cells, Transplantation, Autologous, Autoimmune Diseases
Abstract

In phase I (safety) trials, we have demonstrated the feasibility of autologous hematopoietic stem cell transplantation (HSCT) for patients with autoimmune diseases. Although this review comments on results of our phase I trials, the focus is on phase II (efficacy) trials using gene-marked autologous stem cells.

Published
2000

14. Psychological effects of bone marrow transplantation on children and adolescents: preliminary report of a longitudinal study

Author

S, Phipps, M, Brenner, H, Heslop, R, Krance, D, Jayawardene, and R, Mulhern

Subjects
Male, Adolescent, Intelligence, Infant, Neuropsychological Tests, Hematologic Diseases, Self Concept, Cognition, Child, Preschool, Neoplasms, Humans, Female, Prospective Studies, Survivors, Child, Social Adjustment, Bone Marrow Transplantation, Follow-Up Studies
Abstract

The number of pediatric bone marrow transplantation (BMT) survivors is growing rapidly, yet little is known about the long-term neuropsychologic and psychosocial sequelae of this procedure. Using a prospective, longitudinal design, 64 pediatric patients undergoing BMT were evaluated with standardized measures of global intelligence, academic achievement and selected tests of neuropsychologic function. In addition, adjustment was assessed with parent and patient report measures of social competence, behavior problems and self-esteem. Patients were evaluated prior to admission for BMT, and again in the period 6-12 months after BMT. Longitudinal findings are reported on an initial cohort of 25 survivors. Cognitive and neuropsychologic function remained stable during the study period. The few significant changes from baseline which were observed were in the direction of improvement, and may be attributed to practice effects. In contrast, declines were observed in patient social competence, self-esteem and general emotional well-being. BMT conditioning regimens appear not to be associated with significant neuropsychologic impairment in the first year after transplant. However, a longer period of follow-up is necessary before neuropsychologic late-effects can be ruled out. The first year after BMT is characterized by significant psychosocial difficulties for survivors. Adjustment issues may provide a more salient focus of study during this time frame.

Published
1995

15. Peritoneal fine structure of inguinal hernia: a transmission electron microscope study

Author

A F, Baradi, B R, Parry, and J H, Heslop

Subjects
Male, Mesothelioma, Microscopy, Electron, Humans, Epithelial Cells, Hernia, Inguinal, Tissue Adhesions, Peritoneum, Epithelium, Peritoneal Neoplasms
Abstract

Fine structure of normal human parietal peritoneum served as control data for recording changes in the fine structure of the peritoneum of hernial sacs. In these sacs, mesothelial cells retracted, rounded up and some of them eventually separated altogether to give rise to wide open intercellular spaces thus creating unhindered passageways (stomata) between the subserosal connective tissue and the cavity of the sacs. There was a considerable collagen build-up in the subserosal fibrous tissue of hernial sacs. Occurrence of this fibrosis is at variance with an accepted surgical concept which suggests a defect in collagen synthesis as the cause of herniation. In some sacs mesothelial nodules and/or peritoneal adhesions were present. Certain cytological changes in the mesothelial cells of hernial sacs showed features in common with cells of malignant tumours in general, and features mimicking malignant mesotheliomas in particular. This is in spite of the fact that thorough gross and light microscopic examination of operative specimens and cytological evaluation of peritoneal effusion failed to reveal any evidence of malignancy. Pathologists should be aware of the consummate ability of mesothelial cells to mimic carcinomas in order to avoid possible diagnostic errors. In this report, an electron micrograph of peritoneal adhesion is being published for the first time in the literature. A syncytium-like firm bond between adjoining mesothelial cells constituted the adhesion which is obviously an irreversible process.

Published
1992

17. Improved Homing of Antigen-Specific T Cells to Hodgkin’s Disease (HD) Tumor Cells by Forced Expression of CCR4 Receptor

Author

Barbara Savoldo, L. Zhang, C.M. Rooney, Helen H. Heslop, Aaron E. Foster, Gianpietro Dotti, A. Di Stasi, and Malcolm K. Brenner

Subjects
Adoptive cell transfer, CD30, biology, T cell, Immunology, Cell Biology, Hematology, Biochemistry, Molecular biology, Interleukin 21, medicine.anatomical_structure, Antigen, hemic and lymphatic diseases, biology.protein, medicine, Cytotoxic T cell, Antibody, CD8
Abstract

One crucial requirement for the success of any adoptive T cell transfer is that the effector T cells should migrate efficiently to the tumor site. Such an effect has been documented following adoptive transfer of Epstein-Barr virus specific cytotoxic T cells (EBV-CTLs). Antigenic stimulus from (normal and malignant) cells persistently infected with EBV led to expansion and sustained survival, and was also associated with activity against the EBV+ HD tumors. Since most HD patients have tumors that are EBV- but CD30+, we attempted to extend this approach by incorporating a CD30 chimeric receptor (CD30CAR) into the EBV-CTLs. Pre-clinical animal studies showed that CD30CAR+ EBV-CTLs readily migrated to EBV+/CD30+ tumors, but had limited capacity to localize to EBV−/CD30+ tumor cells. The likeliest explanation for this observation is that EBV- HD tumors produce the chemokine TARC, which attracts Th2 and regulatory T cells, but has little effect on EBV-CTLs, since these express low levels of the TARC receptor, CCR4. We hypothesized that forced expression of CCR4 by redirected EBV-CTLs would improve their homing to the EBV−/CD30+ HD cells. The full length of CCR4 receptor was cloned into the SFG retroviral vector and used to transduce both activated T cells and EBV-CTLs obtained from 6 and 4 healthy donors, respectively. Expression of CCR4 was 12±8% on activated T cells (mainly on CD4+ cells, 12±6%) and 4±5% on EBV-CTLs. After transduction with a CCR4, but not a control vector, expression of CCR4 increased to 53±24% (CD4+ 27±15% and CD8+ 17±9%) on activated T cells and 30±19% on EBV-CTLs. We then evaluated the capacity of control and transgenic T cells and EBV-CTLs to migrate in response to TARC, using a trans-well migration assay. Migration was tested against different CD30+ tumor lines producing TARC at low (Karpas wild type, 2000pg/mL), measured by ELISA. The percent of cells migrating in the trans-well assay was significantly increased for CCR4 transgenic CD8+ selected T cells (54±11% with Karpas/TARC vs. 8±2% with media vs. 8±4% with Karpas-wt). Migration of control OKT3/28 blasts was less than 15% in all the conditions. Migration was significantly inhibited by the addition of antibody blocking TARC (7 days. These data suggest that the migration of CARCD30 EBV-CTL to EBV−/CD30+ HD can be augmented by co-expressing the CCR4 receptor.

Published
2006
Full Text
View/download PDF

20. Potential Income Effects of the Harkin-Gephardt Proposal on New York Dairy Farms

Author

Harry M. Kaiser, Edward H. Heslop, and Robert A. Milligan

Subjects
Agricultural Finance, Control (management), food and beverages, Sample (statistics), General Medicine, Business, Agricultural economics
Abstract

This article reports the results of research regarding the farm-level implications for New York dairy producers of national mandatory supply control programs for feed grains and milk. The analysis is based on the proposed Harkin-Gephardt Bill which would authorize a mandatory supply control program for milk and the major supported crops. Representative farm budgets were constructed for a sample of dairy farms to assess the possible effects on costs and returns. Some farmers would gain, while others would not. The results suggest that dairy farmers who purchase all of their feed would be worse off, while farmers who grow grain would be better off under the proposed supply control program.

Published
1987
Full Text
View/download PDF

21. Autogenous replantation of the maxillary canine

Author

Ian H. Heslop

Subjects
Postoperative Care, Cuspid, Root Canal Obturation, business.industry, medicine.medical_treatment, Apicoectomy, Maxillary canine, Follow up studies, Dentistry, General Medicine, Transplantation, Autologous, Patient Care Planning, Maxilla, Replantation, medicine, Humans, Surgery, business, Tooth, Follow-Up Studies
Published
1967
Full Text
View/download PDF

22. Surgical emphysema of the face, neck, and upper thoracic wall associated with fracture of the facial skeleton

Author

Ian H. Heslop

Subjects
Emphysema, business.industry, Skull, Mandible, Anatomy, respiratory system, Subcutaneous Emphysema, Fractures, Bone, medicine.anatomical_structure, Otorhinolaryngology, Face, Maxilla, Humans, Medicine, Facial skeleton, Surgery, medicine.symptom, Thoracic Wall, business, Surgical emphysema, Neck, Subcutaneous emphysema, Thoracic wall, Nose
Abstract

Summary The occurrence of surgical emphysema of the face and neck is briefly described with special reference to fractures of the facial skeleton, and the literature on the subject is reviewed. A case is reported of surgical emphysema of the face, neck, and upper thoracic wall associated with fracture of the maxilla, zygomatic bones, nasal bones, and mandible in a patient who repeatedly blew his nose following his injury.

Published
1955
Full Text
View/download PDF

24. Secondary neoplasia of the jaws

Author

Ian H. Heslop

Subjects
Male, medicine.medical_specialty, medicine.medical_treatment, Breast Neoplasms, Mandibular Neoplasms, Excision biopsy, Malignant disease, Scirrhous carcinoma, Radiography, Dental, medicine, Humans, Neoplasm Metastasis, Stage (cooking), Melanoma, Aged, business.industry, Carcinoma, General Medicine, Middle Aged, Neoplastic Cells, Circulating, medicine.disease, Kidney Neoplasms, Surgery, Radiation therapy, Female, business, Renal carcinoma
Abstract

Summary Three cases of secondary mandibular neoplasms are recorded, the primary lesions being a renal carcinoma, a scirrhous carcinoma of the breast and a melanoma of the leg. The management of these conditions is confined to confirmation of the diagnosis by an excision biopsy which serves also to make the patient more comfortable and enables him to eat more normally. The use of radiotherapy or cytotoxic drugs in their present form is probably of very limited value at this stage of disseminated malignant disease.

Published
1964
Full Text
View/download PDF

25. Diabetes insipidus associated with maxillo-facial injuries

Author

John E. Bowerman and Ian H. Heslop

Subjects
Adult, Vasopressin, Pediatrics, medicine.medical_specialty, Adolescent, Injury control, Vasopressins, Accident prevention, Poison control, Unconsciousness, Injury prevention, medicine, Humans, Skull Fractures, business.industry, Accidents, Traffic, General Medicine, Water-Electrolyte Balance, medicine.disease, Surgery, Radiography, Diabetes insipidus, Maxillofacial Injuries, business, Diabetes Insipidus
Abstract

Summary The essential clinical features of three cases of post-traumatic diabetes insipidus associated with maxillo-facial injuries are reported. The physiological principles are indicated and experimental evidence is compared with the onset, severity and duration seen clinically in this condition. The difficulties encountered with diagnosis in the unconscious or confused are explained and the necessity for accurate fluid balance charts emphasised. The treatment with vasopressin is indicated.

Published
1970
Full Text
View/download PDF

26. A two-stage bonded canine transplantation and diodontic implant. A case report

Author

G Wreakes, I H Heslop, M S Cooke, and B G Smith

Subjects
Cuspid, Tooth Eruption, Ectopic, medicine.medical_specialty, Adolescent, Tooth Movement Techniques, business.industry, Dental Bonding, Tooth Resorption, Transplantation, Autologous, Surgery, Incisor, Transplantation, medicine, Dental Implantation, Endosseous, Endodontic, Humans, Female, Implant, Stage (cooking), business, General Dentistry
Published
1978
Full Text
View/download PDF

27. Complications of liver resection for trauma

Author

J. H. Heslop

Subjects
Adult, Male, medicine.medical_specialty, Biliary Fistula, medicine.medical_treatment, Peritonitis, Peptic Ulcer Hemorrhage, Hemorrhage, Postoperative Complications, medicine, Bile, Hepatectomy, Humans, Stomach Ulcer, Liver injury, business.industry, Cysts, Liver Diseases, Biliary fistula, Acute kidney injury, General Medicine, Perioperative, Acute Kidney Injury, Blood Coagulation Disorders, medicine.disease, Surgery, Anti-Bacterial Agents, Liver, Wound Infection, business, Complication
Abstract

The major perioperative complication in cases of liver injury is hœmorrhage. This is usually a technical problem, but it may be seriously aggravated by secondary coagulation defects. As a result, renal shut-down is an ever-present possibility. Most of the later complications derive from infection, liver necrosis and respiratory causes. A patient with liver injury who required 100 pints of blood or its components is reported in order to illustrate these difficulties.

Published
1974

28. Hyponatraemic-hypertensive syndrome due to unilateral renal ischaemia in women who smoke heavily

Author

H, Heslop, A M, Richards, M G, Nicholls, E A, Espiner, H, Ikram, and A H, Maslowski

Subjects
Arteriosclerosis, Ischemia, Hypertension, Smoking, Humans, Female, Syndrome, Middle Aged, Kidney, Combined Modality Therapy, Aged, Hyponatremia
Abstract

The hyponatraemic-hypertensive syndrome due to renal ischaemia is presumed to be uncommon. We describe four patients who presented with this syndrome over a period of 21 months. All were women who smoked heavily and had unilateral atherosclerotic renal ischaemia. Hypokalaemia was present in each patient, and in one case resulted in recurrent ventricular tachycardia. All had noted thirst, polyuria, and weight loss. Initiation of treatment with a converting-enzyme inhibitor reduced arterial pressure precipitously in two patients. Removal of the ischaemic kidney, or chronic therapy with a converting-enzyme inhibitor reversed the biochemical abnormalities and the presenting symptoms, and lowered arterial pressure. Detailed studies in two patients before and after treatment confirmed the central role of the renin-angiotensin system in the development of the hyponatraemic-hypertensive syndrome.

Published
1985

29. Oral leiomyoma--a case report and review of the literature

Author

N. Ravindranathan and Ian H. Heslop

Subjects
Male, medicine.medical_specialty, Leiomyoma, business.industry, Mouth Mucosa, Muscle, Smooth, General Medicine, musculoskeletal system, Oral cavity, medicine.disease, Dermatology, female genital diseases and pregnancy complications, body regions, surgical procedures, operative, Cheek, medicine, Humans, Surgery, Mouth Neoplasms, business, neoplasms, Aged
Abstract

Summary Leiomyoma is rare in the oral cavity. A case is presented and the literature reviewed.

Published
1978

30. The management of deep thermal burns to the head

Author

James H. F. Shaw and John H. Heslop

Subjects
Male, medicine.medical_specialty, Scalp, business.industry, Dental drill, Skull, General Medicine, Skin Transplantation, Middle Aged, Skin transplantation, Transplantation, Autologous, Dental High-Speed Equipment, Surgery, Transplantation, stomatognathic diseases, medicine, Head (vessel), Craniocerebral Trauma, Humans, business, Burns, Aged
Abstract

The management of severe thermal burns of the head with associated bone destruction is discussed, and two patients in this category who were successfully treated by decorticating the dead bone with the high-speed dental drill are presented. The burns in both cases had defied management with alternative techniques, and both patients achieved satisfactory skin coverage five weeks after dental burring.

Published
1980

31. Treatment of skeletal class II deformity by mandibular osteotomy and bone grafting

Author

Ian H. Heslop

Subjects
medicine.medical_treatment, Dentistry, Mandible, Bone grafting, Malocclusion, Angle Class II, Mandibular osteotomy, Ilium, stomatognathic system, Deformity, Medicine, Humans, Orthodontics, Bone Transplantation, business.industry, Mandibular teeth, Alveolar process, General Medicine, Skeletal class, medicine.disease, Chin, Osteotomy, stomatognathic diseases, medicine.anatomical_structure, Surgery, medicine.symptom, Malocclusion, business
Abstract

An operation is described to correct the Angles Class II Division I deformity in the patient who wishes to avoid lengthy orthodontic preparation of the dental arches. Repositioning of the anterior mandibular teeth and alveolar process, together with the chin is achieved without hazard to the teeth or the inferior dental neuro-vascular bundle. Interpositional bone grafting is an essential part of the technique.

Published
1981

32. Peritoneal fine structure of inguinal hernia: a scanning electron microscope study

Author

A F, Baradi, J H, Heslop, and N S, Rao

Subjects
Male, Fibrin, Microvilli, Microscopy, Electron, Scanning, Humans, Female, Hernia, Inguinal, Collagen, Stress, Mechanical, Peritoneum
Abstract

Mesothelial cells of the normal human peritoneum of the anterior abdominal wall are covered with numerous surface microvilli. These cells become partially denuded inside the sacs of direct and indirect inguinal hernias and so lose the protective property the microvillar covering may impart on them. These mesothelial cells of hernial sacs also acquire an extensive surface coat of fibrin-like material, presumably due to the loss of that protective property, which may as a result subject them to adhesions. There is a considerable collagen build-up in the subserosal fibrous tissue of sacs of both direct and indirect inguinal hernias. Such a build-up is at variance with the accepted current surgical concept which suggests a defect in collagen synthesis, rather than a build-up, as the cause of direct hernia.

Published
1986

36. COMPLICATED MAXILLOFACIAL INJURIES

Author

I H, HESLOP

Subjects
Casts, Surgical, Fractures, Bone, Adolescent, Splints, Accidents, Surgical Procedures, Operative, Accidents, Traffic, Maxilla, Humans, Maxillofacial Injuries, Facial Injuries
Published
1964

37. Symphilitic osteomyelitis of the mandible

Author

Ian H. Heslop

Subjects
Adult, Male, medicine.medical_specialty, Penicillins, Late syphilis, Transplantation, Autologous, Orthopaedic clinic, Fracture Fixation, Mandibular Fractures, Fracture fixation, medicine, Humans, Mandibular Diseases, Bone Transplantation, business.industry, Osteomyelitis, Syphilis, Congenital, Mandible, General Medicine, medicine.disease, humanities, Surgery, Splints, Fractures, Ununited, Syphilis, business
Abstract

SYPHILITIC disease of bone is a rare condition and it naturally follows that syphilitic disease of a particular bone will appear clinically, and be reported upon, excessively rarely. Turne r (193o) found evidence of osseous lesions in 8.8 per cent. of 1%ooo cases of late syphilis. Buchman and Leiberman (1941) found lesions in bones in 5 per cent. o f 24oo cases of syphilis at all stages. Speed and Boyd (1936) found the diagnosis o f syphilis o f bones or joints in only 0"5 per cent. o f all cases admit ted to a large orthopaedic clinic.

Published
1968

38. The modern treatment of varicose vein disease

Author

J H, Heslop

Subjects
Outpatient Clinics, Hospital, Ethanol, Rutin, Pregnancy Complications, Cardiovascular, Bandages, Sclerosing Solutions, Skin Diseases, Vulva, Varicose Veins, Appointments and Schedules, Pregnancy, Costs and Cost Analysis, Humans, Female, Follow-Up Studies, New Zealand
Published
1973

39. The burn wound

Author

J H, Heslop

Subjects
Ointments, Sulfonamides, Wound Infection, Humans, Pseudomonas Infections, Hydrogen-Ion Concentration, Water-Electrolyte Balance, Burns
Published
1967

41. Primary pruritus ani

Author

J. H. Heslop

Subjects
medicine.medical_specialty, business.industry, Cathartics, General surgery, Gastroenterology, Hygiene, General Medicine, Colorectal surgery, Lactobacillus acidophilus, Pruritus Ani, Surgical oncology, medicine, Humans, Condiments, business, Diet Therapy
Published
1966

42. The application of transplanted tissue in oral surgery

Author

I H Heslop

Subjects
medicine.medical_specialty, Bone Transplantation, business.industry, Oral surgery, Skin Transplantation, Surgery, Oral, Surgery, Text mining, Cartilage, Transplanted tissue, Medicine, Humans, business, General Dentistry, Tooth
Published
1970

46. A technique for the division of the condylar neck of the mandible

Author

Ian H. Heslop

Subjects
Adult, Orthodontics, business.industry, Mandibular Condyle, Mandible, General Medicine, Division (mathematics), Transplantation, Autologous, Condyle, Ilium, Radiography, Recurrence, Odontogenic Cysts, Methods, Humans, Keratins, Medicine, Female, Mandibular Diseases, Surgery, business, Tomography
Published
1972
Full Text
View/download PDF

48. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.

Author

Llaurador G, Shaver K, Wu M, Wang T, Gillispie A, Doherty E, Craddock J, Read J, Yassine K, Morales E, George A, Steffin D, Krance R, Martinez C, Heslop H, and Salem B

Subjects
Humans, Child, Retrospective Studies, Immunoglobulins, Intravenous, Recurrence, Hematopoietic Stem Cell Transplantation adverse effects, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma etiology, Graft vs Host Disease etiology, Graft vs Host Disease prevention & control, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Burkitt Lymphoma etiology, Antibodies, Bispecific
Abstract

Blinatumomab, a bispecific T cell engager that binds CD19 in leukemic cells and CD3 in cytotoxic T cells and leads to leukemic blast lysis, is often used in pediatric patients with relapsed/refractory (R/R) B cell acute lymphoblastic leukemia (B-ALL) prior to allogeneic hematopoietic cell transplantation (allo-HCT). Concerns about the potential risk of blinatumomab-related immune-mediated toxicities after allo-HCT have not been adequately addressed. These include graft-versus-host disease (GVHD), delayed engraftment, and graft failure or rejection. Pediatric-specific data reporting post-HCT outcomes of patients treated with blinatumomab are scarce and limited to small cohorts. We sought to investigate the clinical outcomes of pediatric patients with R/R B-ALL who received blinatumomab therapy pre-HCT, focusing on overall survival (OS), leukemia-free survival (LFS), cumulative incidence of relapse (CIR), and nonrelapse mortality (NRM), as well as the incidence of immune-mediated post-HCT complications including GVHD, delayed neutrophil or platelet engraftment, graft failure, and graft rejection. We also investigated blinatumomab's effects on B cell reconstitution based on achievement of i.v. immunoglobulin (IVIG) independence post-HCT. This single-center, retrospective study included patients with B-ALL receiving blinatumomab therapy before undergoing allo-HCT, with transplantation performed between 2016 and 2021 at our institution. Patients receiving blinatumomab for relapse after allo-HCT were excluded. Patients receiving chemotherapy alone before allo-HCT during the same period composed the control group. Seventy-two patients were included, 31 of whom received blinatumomab before allo-HCT. Survival estimates were obtained using the Kaplan-Meier method, and the log-rank test was used to analyze differences between groups. Categorical variables were compared between groups using the chi-square test or Fisher exact test, and continuous variables were compared using the Wilcoxon rank-sum test. Cumulative incidences were estimated using the competing risks method, and Gray's test was used to analyze differences between groups. A Cox proportional hazards regression model was used for univariate and multivariable analyses for OS. Landmark analysis was performed at the set time points of 30 days and 100 days post-allo-HCT. Most patients in the study cohort had high-risk relapsed B-ALL. Blinatumomab therapy induced minimal residual disease (MRD)-negative remissions in all patients, whereas 5 patients (12.2%) receiving chemotherapy alone had persistent MRD pre-allo-HCT. Time from the start of therapy to the date of allo-HCT was shorter for patients who received blinatumomab compared with those who received chemotherapy (P < .0001). Blinatumomab therapy was associated with greater LFS compared to chemotherapy alone (P = .049), but when limited to 1 year, LFS was not significantly different from control (P = .066). There appeared to be higher OS, lower CIR, and lower NRM in patients receiving blinatumomab compared to the control group; however, the differences were not significant. None of the variables assessed in multivariable analysis was associated with differences in OS. When compared to the controls, blinatumomab therapy did not result in a higher incidence of acute or chronic GVHD, delayed neutrophil or platelet engraftment, or graft failure or rejection. The time to IVIG infusion independence post-allo-HCT was similar in the 2 groups. This study supports the use of blinatumomab salvage therapy for R/R B-ALL before allo-HCT given its efficacy in inducing MRD-negative remissions and optimizing LFS, as well as its lack of association with an increased incidence of post-allo-HCT adverse immune-mediated toxicities. Larger, prospective studies are needed to confirm these findings and to investigate blinatumomab's effects in long-term post-allo-HCT events., (Copyright © 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

49. Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies.

Author

Wang D, Porter CE, Lim B, Rosewell Shaw A, Robertson CS, Woods ML, Xu Y, Biegert GGW, Morita D, Wang T, Grilley BJ, Heslop H, Brenner MK, and Suzuki M

Subjects
Mice, Animals, Adenoviridae genetics, Cytokines, Cell Line, Tumor, Tumor Microenvironment, Oncolytic Virotherapy adverse effects, Oncolytic Viruses, Neoplasms pathology
Abstract

We show that a binary oncolytic/helper-dependent adenovirus (CAdVEC) that both lyses tumor cells and locally expresses the proinflammatory cytokine IL-12 and PD-L1 blocking antibody has potent antitumor activity in humanized mouse models. On the basis of these preclinical studies, we treated four patients with a single intratumoral injection of an ultralow dose of CAdVEC (NCT03740256), representing a dose of oncolytic adenovirus more than 100-fold lower than used in previous trials. While CAdVEC caused no significant toxicities, it repolarized the tumor microenvironment with increased infiltration of CD8 T cells. A single administration of CAdVEC was associated with both locoregional and abscopal effects on metastases and, in combination with systemic administration of immune checkpoint antibodies, induced sustained antitumor responses, including one complete and two partial responses. Hence, in both preclinical and clinical studies, CAdVEC is safe and even at extremely low doses is sufficiently potent to induce significant tumor control through oncolysis and immune repolarization.

Published
2023
Full Text
View/download PDF

50. Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials.

Author

Cornetta K, Yao J, House K, Duffy L, Adusumilli PS, Beyer R, Booth C, Brenner M, Curran K, Grilley B, Heslop H, Hinrichs CS, Kaplan RN, Kiem HP, Kochenderfer J, Kohn DB, Mailankody S, Norberg SM, O'Cearbhaill RE, Pappas J, Park J, Ramos C, Ribas A, Rivière I, Rosenberg SA, Sauter C, Shah NN, Slovin SF, Thrasher A, Williams DA, and Lin TY

Subjects
Humans, Genetic Vectors genetics, Cell Line, Genetic Therapy adverse effects, Virus Replication, Retroviridae genetics
Abstract

The clinical impact of any therapy requires the product be safe and effective. Gammaretroviral vectors pose several unique risks, including inadvertent exposure to replication competent retrovirus (RCR) that can arise during vector manufacture. The US FDA has required patient monitoring for RCR, and the National Gene Vector Biorepository is an NIH resource that has assisted eligible investigators in meeting this requirement. To date, we have found no evidence of RCR in 338 pre-treatment and 1,595 post-treatment blood samples from 737 patients associated with 60 clinical trials. Most samples (75%) were obtained within 1 year of treatment, and samples as far out as 9 years after treatment were analyzed. The majority of trials (93%) were cancer immunotherapy, and 90% of the trials used vector products produced with the PG13 packaging cell line. The data presented here provide further evidence that current manufacturing methods generate RCR-free products and support the overall safety profile of retroviral gene therapy., Competing Interests: Declaration of interests Indiana University has licensed technology to Charles River Laboratories and Genezen Inc. based on unrelated work developed by K.Co., L.D., and T-Y. L., who each receive royalties. P.A.S receives research funding from ATARA Biotherapeutics; Scientific Advisory Board and Consultant: ATARA Biotherapeuticcs, Bayer, Carisma Therapeutics, Imugene, ImmPactBio, Johnston & Johnston, Orion, Outpace Bio; research funding and intellectual property licensed to ATARA Biotherapeutics. M.B. has equity in AlloVir, Marker Therapeutics, and Tessa Therapeutics; serves on the Scientific Advisory Board for Tessa Therapeutics, Marker Therapeutics, Allogene, Walking Fish, Cell Genix, Kuur, Turnstone Biologics, Posedia, Tscan, and Bluebird Bio; and receives royalities from Takeda and Bellicum. K.Cu. is a consultant to Novartis and receives research support from Novartis, Cellectis, and Celgene. B.G. has equity in AlloVir, QBRegulatory LLC, and QBRegulatory, and provides consulting services to AlloVir, Marker Therapeutics, Tessa Therapeutics, Lokon Pharma and Proxima Clinical Research. H.H. has equity in AlloVir and Marker Therapeutics, and serves on the Scientific Advisory Board for Gilead Biosciences, Novartis, Tessa Therapeutics, Marker Therapeutics, Kiadis, PACT Pharma, Mesoblast, and receives research support from Tessa Therapeutics and Kuur Therapeutics. C.S.H. performs consulting and advisory board services for Neogene Therapeutics, Capstan Therapeutics, GlaxoSmithKline, and PACT Pharma; patents and royalties for NIH patents in cell and gene therapy and immunotherapy; research funding from Neogene Therapeutics and T-Cure Biosciences. J.K. has research support and royalty from Kite, a Gilead Company; and receives research funding from Bristol-Myers Squibb, Royalties: Kyverna. D.B.K. is a paid Scientific Advisory Board member for Allogene Therapeutics, ImmunoVec, Pluto Therapeutics, MyoGene Bio, Innoskel and an ad hoc consultant for Cimeio Therapeutics, TransformaTx, and Bluebird Bio. S.M. receives research funding from Allogene Therapeutics, Takeda Oncology, Juno Therapeutics, Bristol-Myers Squibb, Janssen Oncology, Fate Therapeutics and serves on the advisory panel for Legend Biotech, Evicore, Janssen Oncology, BioAscend, Optum Oncology, and EcoR1; and receives honoraria from Plexus Communication, OncLive, Physician Education Resource. R.O. receives compensation from Tesaro/GSK, Regeneron, Seattle Genetics, Fresenius Kabi, Gynecologic Oncology Foundation, Bayer, Curio/Onclive, R-Pharm, Immunogen, Hitech Health; non-compensated steering committee member for the PRIMA, Moonstone (Tesaro/GSK) and DUO-O (AstraZeneca) studies; non-compensated advisor for Carina Biotech. A.R. has received honoraria from consulting with Amgen, Bristol-Myers Squibb and Merck, is or has been a member of the scientific advisory board and holds stock in Advaxis, Appia, Apricity, Arcus, Compugen, CytomX, Highlight, ImaginAb, ImmPact, ImmuneSensor, Inspirna, Isoplexis, Kite-Gilead, Lutris, MapKure, Merus, PACT, Pluto, RAPT, Synthekine and Tango; and has received research funding from Agilent and from Bristol-Myers Squibb through Stand Up to Cancer (SU2C), and patent royalties from Arsenal Bio. C.R. is Scientific Board Member for Novartis; research support from Tessa Therapeutics and Kuur Therapeutics. I.R. has equity or property rights with FloDesign Sonics, Takeda Pharmaceuticals, Fate Therapeutics, Mnemo Therapeutics, Juno Therapeutics; Services and Travel: Center for Commercialization of Cancer, Akron. C.S. is a consultant for Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite/a Gilead Company, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics, and GSK; research funds: Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals and Sanofi-Genzyme. S.S.: research funding: Sanofi-Aventis, Poseida Pharmaceuticals, Gilead Sciences, Inc, Prostate Cancer Foundation; Honoraria: Physician Education Resources, Janssen, Pfizer, Tolmar. D.A.W. holds intellectual property rights to the vector utilized in the trial reported in this manuscript., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results